Invvax, Inc.

Invvax, Inc. is a corporate, for-profit organization registered in SAM.gov since March 2013, with registration valid through July 2026. The company appears to be a biotechnology research firm focused on developing innovative medical solutions, particularly in the realm of antibody engineering and infectious disease prevention. Primarily operating through Small Business Innovation Research (SBIR) grants, Invvax, Inc. specializes in advanced biotechnological research that aims to create transformative medical technologies with potential widespread healthcare applications.

The company has received multiple federal grants from agencies like the National Science Foundation (NSF) and the Department of the Army Medical Command, focusing on developing stable prophylactic antibodies (SPABs) and advanced gene therapy approaches. Specifically, Invvax, Inc. has been awarded grants to conduct research on extending antibody stability for preventing infectious diseases such as influenza, malaria, tuberculosis, HIV, and the common cold. In one significant project with the Department of the Army, the company received $1,878,970 to research genome mapping of the hepatitis B virus and improve CRISPR/Cas gene therapy techniques. Another NSF-funded project involves engineering antibody mutations to resist degradation and enhance receptor binding, with the ultimate goal of creating long-lasting preventative treatments that could potentially be administered once in a lifetime. These grants, ranging from $255,927 to $1,878,970, demonstrate Invvax's commitment to innovative medical research with potential broad-scale healthcare implications.